Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 5/20 | 0.36 |
| ▸ | GLI1 | P08151 | 1/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.35 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | SCN4A | P35499 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13519375 | 0.91 | NOS2 (0.35) | NOS2NOS3NOS1PRCPDPP4 | |
| Serine SCHEMBL181142 | 0.86 | NOS2 (0.32) | NOS2NOS3NOS1ELANE | |
| SCHEMBL542283 | 0.85 | NOS2 (0.39) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL1508068 | 0.85 | MEN1 (0.39) | NOS2NOS3NOS1 | |
| SCHEMBL9362980 | 0.84 | PRCP (0.44) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL30265157 | 0.84 | PRCP (0.44) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL5633667 | 0.84 | DPP4 (0.39) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL28233738 | 0.83 | NOS2 (0.37) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL6859669 | 0.82 | NOS2 (0.46) | NOS2NOS3NOS1PRCPDPP4 | |
| SCHEMBL995604 | 0.82 | NOS2 (0.46) | NOS2NOS3NOS1PRCPDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 362 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026047716-A1 | SARS-COV-2 VACCINES AND THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2026-03-05 | — | — | WO | claimed |
| CN-121577901-A | Urine metabolism marker combination for distinguishing benign kidney diseases from kidney cancers and application thereof | 哈尔滨脉图精准技术有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-20250353797-A1 | ENDOPHYTES, ASSOCIATED COMPOSITIONS, AND METHODS OF USE | INDIGO AG INC (US) | 2025-11-20 | — | — | US | claimed |
| EP-4642481-A2 | MULTITARGET VACCINES AND THERAPEUTICS | Popvax Private Limited (IN) | 2025-11-05 | — | — | EP | claimed |
| WO-2025088052-A1 | CYCLIC ANALOGUE OF GLYCINE-PROLINE FOR USE IN THE PREVENTION AND/OR TREATMENT OF MEDICAL IMPLANT-RELATED FIBROSIS | ROUSSELOT BV (BE) | 2025-05-01 | — | — | WO | claimed |
| CN-119855584-A | Formulations comprising anti-Claudin18.2 and CD3 bispecific antibodies, methods of making and uses thereof | 信达生物制药(苏州)有限公司 | 2025-04-18 | — | — | CN | claimed |
| CN-119224161-A | Method for detecting various dipeptides in rumen fluid of ruminant | 中国科学院亚热带农业生态研究所 | 2024-12-31 | — | — | CN | claimed |
| CN-118703593-A | Argininase quantitative detection kit, argininase qualitative detection kit and use method thereof | 武汉简为医疗科技有限公司 | 2024-09-27 | — | — | CN | claimed |
| CN-118384255-A | Application of walnut peptide in preparation of obesity improving medicine | 云南中医药大学 | 2024-07-26 | — | — | CN | claimed |
| WO-2024141786-A2 | MULTITARGET VACCINES AND THERAPEUTICS | POPVAX PRIVATE LIMITED (IN) | 2024-07-04 | — | — | WO | claimed |
| EP-1572720-A2 | METHOD FOR ENZYMATIC PRODUCTION OF GLP-2(1-33) AND GLP-2-(1-34) PEPTIDES | NPS Allelix Corp. (CA) | 2005-09-14 | — | — | EP | claimed |
| WO-2003099854-A2 | METHOD FOR ENZYMATIC PRODUCTION OF GLP-2(1-33) AND GLP-2-(1-34) PEPTIDES | NPS ALLELIX CORP. (CA) | 2003-12-04 | — | — | WO | claimed |
| US-20020147317-A1 | Fluorogenic compounds and uses therefor | 3M INNOVATIVE PROPETIES COMPANY | 2002-10-10 | — | — | US | claimed |
| US-6372895-B1 | USEFUL IN ASSAYING FOR BIOLOGICAL ACTIVITY | 3M INNOVATIVE PROPERTIES COMPANY | 2002-04-16 | — | — | US | claimed |
| EP-0416282-B1 | Microbiologically produced N-Acyl-L-proline-acylase, process for its production and its use | DEGUSSA (DE) | 1994-09-14 | — | — | EP | claimed |
| US-5219741-A | Reacting in the presence of microbiologically produced N-acyl-L-proline acylase | DEGUSSA AG (DE) | 1993-06-15 | — | — | US | claimed |
| US-5120652-A | Synthesis of proline from acyl derivatives; thermostable | DEGUSSA AG (DE) | 1992-06-09 | — | — | US | claimed |
| EP-0210257-A4 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS. | HURWITZ CHARLES (US) | 1988-01-20 | — | — | EP | claimed |
| EP-0210257-A1 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS | HURWITZ, Charles (US) | 1987-02-04 | — | — | EP | claimed |
| WO-1986004588-A1 | PROTEIN WHICH IS CHARACTERISTIC OF RHEUMATOID ARTHRITIS | HURWITZ CHARLES (US) | 1986-08-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147317-A1 | Fluorogenic compounds and uses therefor | NOTUM, WEE1, CPSF7 | NOS2 2476/4885NOS3 1755/4885NOS1 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.